guest ::
| Home > Articles > Published articles > Rapid and direct quantification of the SARS-CoV-2 virus with an ultrasensitive nanobody-based photonic nanosensor |
| Home > Articles > Published articles > Rapid and direct quantification of the SARS-CoV-2 virus with an ultrasensitive nanobody-based photonic nanosensor |
(Institut Català de Nanociència i Nanotecnologia) (Institut Català de Nanociència i Nanotecnologia) (Institut Català de Nanociència i Nanotecnologia) (Institut Català de Nanociència i Nanotecnologia) (Consejo Superior de Investigaciones Científicas. Centro Nacional de Biotecnología) (Institut Català de Nanociència i Nanotecnologia)
| Date: | 2022 |
| Abstract: | The coronavirus (CoV) disease 2019 (COVID-19) is expected to become endemic in the coming years, meaning that the worldwide society shall be prepared to routinely manage the highly contagious respiratory SARS-CoV-2. A rapid and early diagnosis of the SARS-CoV-2 infection is crucial for controlling the spread of the disease, interrupting the transmission chain, and providing timely medical attention to patients. We introduce an innovative nanophotonic biosensor for the quantitative detection of viral particles in less than 20 minutes total assay time. The nanosensor, based on the bimodal waveguide (BiMW) interferometric technology, has been functionalized with novel bioengineered nanobodies (Nb) targeting the SARS-CoV-2 receptor-binding domain (RBD). Our approach relies on the direct capture of the viral particles, and the optimized methodology allows the detection of the SARS-CoV-2 virus with outstanding sensitivity, below 200 TCID50 per mL, being able to provide accurate viral load determination within a broad dynamic range (102-106 TCID50 per mL). Both the nanobodies and the sensor nanotechnology can be produced at a large scale with highly-efficient cost-effective procedures, and they are being integrated into a user-friendly point-of-care device for multiplexed and decentralized operation. The implementation of this unique biosensor in primary care assistance, hospitals, pharmacies, or private laboratories could greatly aid in the relief and descongestion of the sanitary systems and the clinical and social management of COVID-19. |
| Grants: | European Commission 101003544 European Commission 871029 European Commission 653316 Agencia Estatal de Investigación SEV-2017-0706 |
| Note: | Altres ajuts: this work has been funded by the European Commission - NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global - Iniciativa Estratégica de Diagnóstico). The ICN2 is funded by the CERCA Program/Generalitat de Catalunya. Work in CNB-CSIC was funded by the Spanish Ministry of Science and Innovation (MICIN) and the Spanish Research Council (CSIC) under grants PIE-RD-COVID 19 (No 202020E079) and PTI Salud Global REC_EU (No SGL 2103051, NextGenerationEU). Work at I2SysBio was funded by Ayudas de concesión directa a soluciones científico-innovadoras directamente relacionadas con la lucha contra la Covid-19 grant from the Generalitat Valenciana, Spanish National Research Council grant CSIC-COV19-082/104, Fondo Supera Covid-19 grant BlockAce, and European Commission - NextGenerationEU to Ron Geller. |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Published in: | Sensors & Diagnostics, Vol. 1, issue 5 (Sep. 2022) , p. 983-993, ISSN 2635-0998 |
